Log in

NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

$50.34
-1.09 (-2.12 %)
(As of 04/2/2020 06:54 AM ET)
Today's Range
$49.10
Now: $50.34
$52.27
50-Day Range
$40.22
MA: $50.86
$55.72
52-Week Range
$38.40
Now: $50.34
$101.27
Volume269,972 shs
Average Volume303,417 shs
Market Capitalization$1.00 billion
P/E Ratio31.07
Dividend YieldN/A
Beta0.73
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Read More
Enanta Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$205.20 million
Cash Flow$2.25 per share
Book Value$23.50 per share

Profitability

Net Income$46.38 million

Miscellaneous

Employees113
Market Cap$1.00 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.


Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

How has Enanta Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ENTA shares have decreased by 4.9% and is now trading at $50.34. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Enanta Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Enanta Pharmaceuticals.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Enanta Pharmaceuticals.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its quarterly earnings data on Thursday, February, 6th. The biotechnology company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.06. The biotechnology company earned $52.57 million during the quarter, compared to analyst estimates of $58.75 million. Enanta Pharmaceuticals had a return on equity of 7.39% and a net margin of 18.00%. The company's revenue was down 24.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.25 earnings per share. View Enanta Pharmaceuticals' earnings history.

What price target have analysts set for ENTA?

5 Wall Street analysts have issued 1-year price targets for Enanta Pharmaceuticals' shares. Their forecasts range from $57.00 to $130.00. On average, they expect Enanta Pharmaceuticals' share price to reach $91.00 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals.

Has Enanta Pharmaceuticals been receiving favorable news coverage?

News coverage about ENTA stock has been trending very negative on Thursday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutEnanta Pharmaceuticals.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a drop in short interest in February. As of February 28th, there was short interest totaling 1,940,000 shares, a drop of 8.5% from the February 13th total of 2,120,000 shares. Based on an average daily trading volume, of 214,100 shares, the short-interest ratio is currently 9.1 days. Approximately 11.0% of the shares of the stock are sold short. View Enanta Pharmaceuticals' Current Options Chain.

Who are some of Enanta Pharmaceuticals' key competitors?

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), Wells Fargo & Co (WFC), NVIDIA (NVDA), Ford Motor (F), Alibaba Group (BABA) and Tesla (TSLA).

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 63)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $50.34.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.00 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe. View additional information about Enanta Pharmaceuticals.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  592
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Featured Article: What is Compound Interest?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel